Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 19
- Registration Number
- NCT03854903
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 198
- Registration Number
- NCT03809988
- Locations
- 🇩🇪
AGAPLESION Markus Krankenhaus, Frankfurt, Germany
🇮🇹Ospedale Civili Brescia, Brescia, Italy
🇸🇮Onkološki Inštitut Ljubljana, Ljubljana, Slovenia
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
- Conditions
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 12
- Registration Number
- NCT03792256
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Molecular Profiling of Advanced Soft-tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 603
- Registration Number
- NCT03784014
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷IUCT Oncopôle, Toulouse, France
🇫🇷Institut de Cancérologie de Montpellier, Montpellier, France
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03774472
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03756090
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT03709680
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT03709082
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas, United States
🇺🇸The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
🇺🇸The University of Kansas Cancer Center, West Clinic, Kansas City, Kansas, United States
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 38
- Registration Number
- NCT03691493
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 54
- Registration Number
- NCT03685331
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.